Does Mounjaro help with fertility — and is it safe to try?

What the clinical data shows about obesity, weight loss, and hormonal function

The link between excess body weight and impaired fertility is well-established in the medical literature. Adipose tissue is hormonally active: it converts androgens to oestrogens, disrupts the hypothalamic-pituitary-ovarian axis, and raises circulating insulin levels, all of which can suppress or irregular ovulation. In polycystic ovary syndrome, which is the most common cause of anovulatory infertility in the UK, insulin resistance sits at the centre of the hormonal disruption, and the condition is both worsened by and a driver of weight gain.

Tirzepatide's dual action on GIP and GLP-1 receptors does more than reduce appetite. It substantially lowers fasting insulin, improves insulin sensitivity, and reduces markers of systemic inflammation. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants using the 15mg dose achieved an average weight reduction of around 20–21% over 72 weeks, a magnitude of loss associated in other research with restoration of ovulatory cycles in women with obesity-related anovulation. The trial was not designed to measure fertility outcomes directly, so the reproductive effects are inferred from weight-loss and metabolic data rather than counted as primary endpoints. That matters: the evidence is plausible and encouraging, but it is not the same as a randomised controlled trial of Mounjaro as a fertility intervention.

For men, obesity is associated with lower testosterone, reduced sperm quality, and elevated oestrogen, changes that can affect both libido and conception rates. You can read more about that specific picture on our page covering Mounjaro's potential effects on male fertility.

Why Mounjaro cannot be used when you are actively trying to conceive

This is the part of the answer that tends to surprise people. Mounjaro is explicitly not recommended during pregnancy or while trying to conceive. The SmPC (the prescriber reference document) and NHS guidance both advise stopping tirzepatide at least one month before attempting pregnancy, because animal studies have raised concerns about developmental effects at high doses and because there is simply not yet enough human data to establish safety in early pregnancy.

The NHS medicines information for tirzepatide makes this explicit: women who could become pregnant should use effective contraception during treatment. Critically, for those relying on the oral contraceptive pill, Mounjaro slows gastric emptying and can reduce pill absorption during the first four weeks of treatment and for four weeks after each dose increase. NHS guidance recommends adding a barrier method during those windows. Our page on how Mounjaro affects fertility broadly covers the contraception detail at more length if you want the fuller picture.

The same guidance applies to breastfeeding: Mounjaro is not recommended, and under-18s are not within the licensed population at all. If you are at the stage of actively trying to conceive, the right time for this conversation is with your GP or fertility specialist before you start treatment, not after.

What the uncertainty looks like, and who should guide your decision

Honest medicine acknowledges what it does not yet know. There are no completed prospective trials measuring live birth rates or time-to-conception as primary outcomes in people using tirzepatide. The NICE appraisal of tirzepatide (TA1026) addresses weight management in adults and does not make recommendations about reproductive outcomes. Guidance in this area is built on mechanistic reasoning, observational data from bariatric surgery and earlier GLP-1 medicines, and the known effects of weight loss on hormones, all of which point in the same direction, but none of which constitute a clinical trial of fertility specifically.

If your goal is to improve fertility through weight loss, and you are not yet at the stage of actively trying to conceive, Mounjaro may be clinically appropriate for a period before you start trying, provided you use reliable non-oral contraception throughout. The decision requires a conversation that takes in your full medical history, current cycle pattern, any fertility investigations already done, and any medicines you are already taking. That is not something to shortcut.

Our overview of tirzepatide's pregnancy classification and safety data goes into the regulatory detail more precisely for anyone who wants to read the formal guidance rather than a summary. And if broader questions about the treatment have come up (lifestyle, alcohol, other medicines) our frequently asked questions may be a useful starting point alongside a clinical conversation.

How to approach this with a prescriber

If you are considering Mounjaro in the context of fertility, the clearest path is to be explicit about your timeline. Tell whoever reviews your consultation that conceiving is a goal within the next one to two years, because that changes several clinical decisions: how long treatment might run, which contraception you use during it, when to plan stopping, and whether a fertility specialist should be looped in from the beginning.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the day it is submitted. The consultation asks about your medical history in enough detail that your plans around conception can inform the clinical assessment. If treatment is approved as clinically suitable, it is dispatched the same day for free next-working-day delivery. If this situation is yours, weight affecting reproductive health, a desire to improve things before trying to conceive, and uncertainty about whether Mounjaro fits, our pages on Mounjaro and fertility and whether Mounjaro impacts fertility are worth reading before a free consultation, which remains the appropriate next step alongside that conversation with your GP or specialist.